{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:56:09Z","timestamp":1776808569811,"version":"3.51.2"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the safety and clinical efficacy of two anti\u2010angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      Eligible patients with metastatic castration\u2010resistant prostate cancer enrolled in this open\u2010label, phase\n                      <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                      study of lenalidomide with bevacizumab (15 mg\/kg), docetaxel (75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and prednisone (10 mg daily). Docetaxel and bevacizumab were administered on day 1 of a 3\u2010week treatment cycle. To establish safety, lenalidomide dosing in this combination was escalated in a conventional 3 + 3 design (15, 20 and 25 mg daily for 2 weeks followed by 1 week off). Patients received supportive measures including prophylactic pegfilgrastim and enoxaparin. The primary endpoints were safety and clinical efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 63 patients enrolled in this trial. Toxicities were manageable with most common adverse events (\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s) being haematological, and were ascertained by weekly blood counts. Twenty\u2010nine patients (46%) had grade 4 neutropenia, 20 (32%) had grade 3 anaemia and seven (11%) had grade 3 thrombocytopenia. Despite frequent neutropenia, serious infections were rare. Other common non\u2010haematological grade 3\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s included fatigue (10%) and diarrhoea (10%). Grade 2\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s in &gt;10% of patients included anorexia, weight loss, constipation, osteonecrosis of the jaw, rash and dyspnoea. Of 61 evaluable patients, 57 (93%), 55 (90%) and 33 (54%) had\n                      <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                      declines of &gt;30, &gt;50 and &gt;90%, respectively. Of the 29 evaluable patients, 24 (86%) had a confirmed radiographic partial response. The median times to progression and overall survival were 18.2 and 24.6 months, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With appropriate supportive measures, combination angiogenesis inhibition can be safely administered and potentially provide clinical benefit. These hypothesis\u2010generating data would require randomized trials to confirm the findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13412","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T09:20:54Z","timestamp":1453108854000},"page":"590-597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase\n                    <scp>II<\/scp>\n                    trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration\u2010resistant prostate cancer"],"prefix":"10.1111","volume":"118","author":[{"given":"Ravi A.","family":"Madan","sequence":"first","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima H.","family":"Karzai","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang\u2010Min","family":"Ning","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bamidele A.","family":"Adesunloye","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Harold","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Couvillon","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guinevere","family":"Chun","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Cordes","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Sissung","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaunna L.","family":"Beedie","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Dawson","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center Georgetown University Washington D.C. USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R.","family":"Theoret","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"McLeod","sequence":"additional","affiliation":[{"name":"Center for Prostate Disease Research Walter Reed National Military Medical Center Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Rosner","sequence":"additional","affiliation":[{"name":"Center for Prostate Disease Research Walter Reed National Military Medical Center Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min\u2010Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tomita","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Chen","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Arlen","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Dahut","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8404"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2015.33.15_suppl.5001","article-title":"Docetaxel and\/or zoledronic acid for hormone\u2010na\u00efve prostate cancer: first overall survival results from STAMPEDE (NCT00268476)","volume":"33","author":"James ND","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8825"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4767"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70025-2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70184-0"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708148104"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4524"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0302"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2701-3"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03896.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27387"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.59"},{"key":"e_1_2_6_24_1","volume-title":"Cereblon (CRBN) gene polymorphisms predict clinical response and progression\u2010free survival in multiple myeloma patients treated with lenalidomide: a pharmacogenetic study of immense consortium","author":"Iskierka\u2010Jazdzewska E","year":"2014"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.7.3536"},{"key":"e_1_2_6_27_1","article-title":"Phase III SYNERGY trial: docetaxel +\/\u2010 custirsen and overall survival in patients with metastatic castration\u2010resistant prostate cancer and poor prognosis","volume":"33","author":"Chi KN","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3100"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4025"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279893"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:42:34Z","timestamp":1761730954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,19]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/bju.13412"],"URL":"https:\/\/doi.org\/10.1111\/bju.13412","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,19]]},"assertion":[{"value":"2016-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}